UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", the "Company," "we" and "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the "Offer Shares"). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30- ...

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab ...

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtama ...

Shares of Merus N.V. (MRUS) rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its investigational antibody, petosemtamab and Merck’s blockbuster oncology drug Keytruda.This study evaluated the petosemtamab/Keytruda combination as a first-line treatment for patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).As of the Nov 6, 2023 cut-off date, 26 patients had been treat ...

-   60% response rate observed among 10 evaluable patients -   Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed -   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibod ...

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ann ...

Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of (I. ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung ...

Merus N.V. (MRUS) shares soared 7.1% in the last trading session to close at $44.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.2% loss over the past four weeks.Last month, the company entered into a collaboration and license agreement with Gilead Sciences to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies and develop multiple separate preclinical research programs. This might have driv ...